|
楼主 |
发表于 2015-5-4 11:32 PM
|
显示全部楼层
SUPN, heal,supernus pharm,drugs-genrc,cap 619840000.0,sh 46780377.36 SUPN yh fvz gg fool msn stox j3 a
["pe 38.97,eps 113.4 113.8,p_b 7.98,", "p_fcf 238.4,alpha 82.06,a_vol 602600, insi 1.5 -1.21,inst 80.3 -3.47,recom 2.00"]
=================
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its marketed products include Oxtellar XR, an extended-release oxcarbazepine and Trokendi XR, an extended-release topiramate, which are neurology products used for the treatment of epilepsy. The company products also comprise SPN-810, a molindone hydrochloride that has completed Phase II clinical trials for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIa clinical trials for the treatment of ADHD. In addition, it is developing SPN-809, a viloxazine hydrochloride as a once-daily product candidate for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
=================
=================
|
|